Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. McKay on the Rationale for Triplet Frontline Therapy in RCC

November 22nd 2022

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC

November 22nd 2022

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Rapid Developments Generate Waves of Excitement for Patients With RCC

November 17th 2022

A variety of factors must be considered for treatment decisions for patients with renal cell carcinoma due to the expanded number of options available to clinicians.

Dr. McKay on Future Directions For mRCC Research

November 16th 2022

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.

CTX130 Allogeneic CAR T-cell Therapy Shows Tolerability, Intriguing Activity in Advanced RCC

November 11th 2022

CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.

Future Directions in the Management of Renal Cell Carcinoma

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Clinical End Points and Trial Designs Undergo Evolution in RCC

November 8th 2022

Chung-Han Lee, MD, PhD, outlines common clinical trial end points in renal cell carcinoma and those that may provide a more complete picture of a drug’s activity, particularly as the standard of care evolves.

CA-125 Level Correlates With Response, Progression in Renal Medullary Cancer

November 7th 2022

CA-125 levels increased as renal medullary carcinoma worsened and decreased with treatment response.

Nivolumab/Ipilimumab Plus CBM588 Generates Superior Efficacy in Metastatic RCC

November 7th 2022

The addition of CBM588 to the combination of nivolumab and ipilimumab produced superior response rates and a progression-free survival benefit vs nivolumab plus ipilimumab alone in previously untreated patients with metastatic renal cell carcinoma.

Emerging Therapies Prompt Nuanced AE Management in Kidney Cancer

November 6th 2022

Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.

Investigators Debate Frontline Doublet Vs Triplet Therapy in RCC

November 5th 2022

Rana M. McKay, MD, and Yousef Zakharia, MD, debate the pros and cons of doublet vs triplet combination therapies in the frontline setting for patients with renal cell carcinoma.

Tivozanib Maintains Long-Term PFS Benefit Over Sorafenib in Relapsed/Refractory RCC

November 5th 2022

Tivozanib continued to display a progression-free survival benefit and rates vs sorafenib in patients with relapsed/refractory renal cell carcinoma who received 2 or 3 prior systemic regimens.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Nivolumab/Ipilimumab Improves Survival in Untreated, Advanced Sarcomatoid RCC

November 4th 2022

The combination of nivolumab and ipilimumab led to significant improvements in survival vs sunitinib in patients with intermediate- and poor-risk renal cell carcinoma with sarcomatoid features.

Lenvatinib/Pembrolizumab Reduces Need for Subsequent Therapy in Advanced RCC

November 4th 2022

Lenvatinib plus pembrolizumab reduced the need for second-line therapy by 42.8% compared with sunitinib in patients with advanced renal cell carcinoma.

Dr. McGregor on Belzutifan Plus Lenvatinib in Advanced RCC

November 4th 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

Deep Responses Demonstrate Association With Prolonged Survival to Nivolumab/Cabozantinib in mRCC

November 4th 2022

Patients with treatment-naïve advanced renal cell carcinoma who received nivolumab plus cabozantinib achieved deeper objective responses leading to improved progression-free survival and overall survival rates vs those who received sunitinib, according to exploratory data from the CheckMate 9ER trial.

Lenvatinib Plus Everolimus Under Investigation Vs Cabozantinib in PD-1–Pretreated mRCC

November 4th 2022

The combination of lenvatinib plus everolimus is under evaluation vs cabozantinib in the phase 2 LenCabo trial for patients with metastatic renal cell carcinoma who have progressed on prior treatment with a PD-1/PD-L1 immune checkpoint inhibitor.

Dr. McKay on Recent Advancements in the Frontline Treatment of Metastatic RCC

November 4th 2022

Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.